Hercules, CA — January 12, 2015 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the ddPCR™ KRAS Screening Multiplex Kit, the latest offering in the company’s Droplet Digital™ PCR line of predesigned, fully wet-lab validated assays. The ddPCR KRAS Screening Multiplex Kit offers improved sensitivity and simultaneous detection of the seven most common KRAS mutations in a single ddPCR experiment.
KRAS mutations are found in 90% of pancreatic cancer cases and 30% of colorectal cancer cases, making it a gene of great interest to cancer researchers. Used with Bio-Rad’s ddPCR technology, the Multiplex Kit is able to detect and quantify extremely low levels (down to 0.2%) of KRAS mutant DNA in a single assay. Cancer samples are often available in limited quantities. Using the Multiplex Kit, researchers can derive results from low amounts of starting material.
“The KRAS Screening Multiplex Kit delivers a simple yes/no answer as to whether a KRAS mutation exists in smaller samples,” said Dr. Filip Janku of the University of Texas MD Anderson Cancer Center in Houston, TX. “If researchers were to test for the presence of each possible mutation they could end up performing seven to ten separate PCR experiments only to discover the sample was negative. Multiplex kits such as the KRAS Screening Multiplex Kit allow researchers to screen for multiple mutations in a single reaction, saving time and costly resources.”
ddPCR KRAS Screening Multiplex Kits are compatible with all of Bio-Rad’s Droplet Digital PCR Systems, including the QX200™ AutoDG™ Droplet Digital™ PCR System.
For more information on Bio-Rad’s ddPCR KRAS Screening Multiplex Kit, please visit www.bio-rad.com/KRASpr.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Viresh Patel
Bio-Rad Laboratories
925-474-8602
Viresh_Patel@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com